FORT WORTH, Texas, Dec. 11 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., , announced today that it is exploring a potential acquisition of BioPharma Management Technologies, Inc., a company that has recently launched the development of topical pain management products. "While we have been focusing this year on expanding market penetration of our CellerateRx(R) products, we also have been working to expand our current product portfolio. We believe that the science behind BioPharma's product development shows potential and creates market synergies with our current products," says Scott Haire, Wound Management Technologies' CEO. "We believe that BioPharma's products will provide a broad application across several medical specialities. We are not aware of any currently available products in the market that provide the benefits we expect BioPharma's unique formulation to deliver."
BioPharma is developing a topical pain management product targeting the growing pain management market place. "Based on our research, we believe that this product will provide a broad application across several medical specialities while supplying a good safety profile, expanded dosing range and flexibility, and should create and maintain a moist environment conducive to drug absorption and reduction of irritation at the application site. All year we have focused on Cellerate as a one-of-a-kind product and adding an additional company and product mix should make us a leader in the wound industry and related healthcare markets," states Scott Haire, CEO of Wound Management Technologies. "Also this should significantly increase our revenues in 2010 in all areas of wound care."
CellerateRx(R) is exclusively distributed by Wound Care Innovations, a subsidiary of Wound Management Technologies. It is a one-of-a-kind, patented, advanced wound care collagen product and is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, pressure ulcers stage I-IV, venous stasis ulcers, ulcers due to arterial insufficiency, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns. "In 2008, the company has focused on providing additional evidence-based data and has been published in two major wound care publications as well as had a featured speaker at a major wound care conference. Our efforts in 2008 serve to boost customer confidence and will contribute to market success in 2009," states Cathy Bradshaw, President of Wound Care Innovations. "Adding BioPharma's future product mix has the potential to make us a leader in wound care and other medical management areas."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
CONTACT: Product Information, Cathy Bradshaw, President, +1-954-315-9242,
Shareholder Relations, Lucy Singleton, Corporate Secretary,
+1-817-820-7080, both of Wound Management Technologies, Inc.
Web site: http://www.Celleraterx.com/
